Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 791: What is the recommended antimicrobial prophylaxis in adults for influenza A?

A. Penicillin
B. Erythromycin
C. Rifampicin
D. Oseltamivir (Correct Answer)

Explanation: **Explanation:** The correct answer is **Oseltamivir**. Influenza A is a viral respiratory infection caused by the Orthomyxoviridae family. Management involves either treatment of active infection or chemoprophylaxis in high-risk individuals. **Why Oseltamivir is correct:** Oseltamivir is a **Neuraminidase Inhibitor**. Neuraminidase is an enzyme on the viral surface required to cleave sialic acid receptors, allowing the release of newly formed virions from infected host cells. By inhibiting this enzyme, Oseltamivir prevents the spread of the virus within the body. It is the drug of choice for both prophylaxis and treatment of Influenza A and B. For prophylaxis, it is typically administered once daily for 7–10 days following exposure. **Why other options are incorrect:** * **Penicillin & Erythromycin:** These are antibacterial agents. Penicillin targets cell wall synthesis (Gram-positive coverage), and Erythromycin (a Macrolide) inhibits the 50S ribosomal subunit. They have no activity against viruses. * **Rifampicin:** This is an antitubercular drug that inhibits bacterial DNA-dependent RNA polymerase. It is used for TB or as prophylaxis for *Meningococcal* meningitis, not viral infections. **High-Yield Clinical Pearls for NEET-PG:** * **Timing:** For maximum efficacy, Oseltamivir should ideally be started within **48 hours** of symptom onset or exposure. * **Route:** Oseltamivir is administered **orally** (prodrug), whereas **Zanamivir** is inhaled (contraindicated in asthma/COPD due to bronchospasm risk). * **Baloxavir Marboxil:** A newer single-dose drug for Influenza that inhibits **cap-dependent endonuclease**, blocking viral RNA synthesis. * **Amantadine/Rimantadine:** Older M2 ion channel blockers; no longer recommended due to widespread resistance in Influenza A and inherent resistance in Influenza B.

Question 792: Isoniazid may show cross-resistance with which of the following anti-tubercular drugs?

A. Rifampicin
B. Cycloserine
C. Streptomycin
D. Ethionamide (Correct Answer)

Explanation: **Explanation:** The correct answer is **Ethionamide**. **Mechanism of Cross-Resistance:** The cross-resistance between Isoniazid (INH) and Ethionamide is rooted in their shared mechanism of action. Both drugs are **prodrugs** that inhibit **mycolic acid synthesis**, a vital component of the mycobacterial cell wall. * INH is activated by the enzyme **KatG** (catalase-peroxidase) and targets the **InhA** enzyme (enoyl-ACP reductase). * Ethionamide is activated by a different enzyme (**EthA**) but targets the **same InhA enzyme**. * **The Link:** Mutations in the **inhA gene** (promoter region) lead to overexpression of the InhA enzyme. Since both drugs target this specific enzyme, a mutation here results in **cross-resistance** between INH and Ethionamide. (Note: Mutations in the *katG* gene cause high-level resistance to INH only, without affecting Ethionamide). **Why Incorrect Options are Wrong:** * **Rifampicin:** Acts by inhibiting DNA-dependent RNA polymerase (*rpoB* gene mutation). It has a completely different target and activation pathway. * **Cycloserine:** A second-line drug that inhibits peptidoglycan synthesis by acting as an antimetabolite of D-alanine. * **Streptomycin:** An aminoglycoside that inhibits protein synthesis by binding to the 30S ribosomal subunit (*rpsL* or *rrs* gene mutations). **High-Yield Clinical Pearls for NEET-PG:** * **INH Resistance:** Most commonly due to *katG* gene mutation (high-level resistance) or *inhA* gene mutation (low-level resistance + cross-resistance with Ethionamide). * **Ethionamide Side Effects:** Notable for causing intense GI irritation and a metallic taste. * **Fast vs. Slow Acetylators:** INH metabolism depends on N-acetyltransferase 2 (NAT2). Slow acetylators are prone to peripheral neuropathy (prevented by **Pyridoxine/Vit B6**), while fast acetylators may show poor response.

Question 793: Which drug acts by binding to the B site in prokaryotes?

A. Chloramphenicol (Correct Answer)
B. Puromycin
C. Penicillin
D. Actinomycin-D

Explanation: **Explanation:** The correct answer is **Chloramphenicol**. **Mechanism of Action:** Chloramphenicol is a bacteriostatic antibiotic that inhibits protein synthesis by binding to the **50S ribosomal subunit**. Specifically, it binds to the **"B site"** (also known as the peptidyl transferase center) of the 50S subunit. This binding prevents the attachment of the aminoacyl-tRNA to the A site and inhibits the enzyme **peptidyl transferase**, thereby blocking the formation of peptide bonds between amino acids. **Analysis of Incorrect Options:** * **Puromycin:** This is a structural analog of aminoacyl-tRNA. It acts by entering the **A site** and incorporating itself into the growing peptide chain, causing premature chain termination. * **Penicillin:** This is a Beta-lactam antibiotic that inhibits **cell wall synthesis** by binding to Penicillin-Binding Proteins (PBPs), preventing the cross-linking of peptidoglycan. It does not act on ribosomes. * **Actinomycin-D:** This is an antineoplastic drug that binds to **DNA** (intercalation) and inhibits RNA polymerase, thereby blocking transcription. It is not a protein synthesis inhibitor acting on the B site. **High-Yield NEET-PG Pearls:** * **Gray Baby Syndrome:** A classic side effect of Chloramphenicol due to the inability of neonates to conjugate the drug (deficiency of glucuronyl transferase). * **Bone Marrow Suppression:** Can cause dose-dependent anemia or dose-independent **Irreversible Aplastic Anemia**. * **Resistance:** Primarily mediated by the enzyme **Chloramphenicol acetyltransferase**, which inactivates the drug. * **Spectrum:** Highly effective against anaerobes and *Rickettsia*, though its use is limited by toxicity.

Question 794: Which of the following best describes the mechanism of action of nucleoside/nucleotide analogs, such as didanosine, used in highly active antiretroviral therapy (HAART) for HIV patients?

A. They prematurely terminate the DNA synthesized by reverse transcriptase. (Correct Answer)
B. They prevent the hydrolysis of the viral polyprotein.
C. They directly bind to and inhibit reverse transcriptase.
D. They inhibit the synthesis of viral proteins.

Explanation: ### Explanation **Mechanism of Action (Correct Option A):** Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), such as **Didanosine (ddI)**, act as structural analogs of native purines and pyrimidines. To become active, they must undergo intracellular phosphorylation by host cell kinases into triphosphate forms (except Tenofovir, which is a nucleotide and requires only two phosphorylations). These active metabolites compete with natural nucleotides for incorporation into the growing viral DNA chain by **Reverse Transcriptase**. Because these analogs **lack a 3'-hydroxyl (-OH) group**, they prevent the formation of a 5'-3' phosphodiester bond with the next incoming nucleotide, leading to **premature DNA chain termination**. **Analysis of Incorrect Options:** * **Option B:** This describes the mechanism of **Protease Inhibitors (PIs)** like Ritonavir or Lopinavir. They prevent the cleavage of the Gag-Pol polyprotein into functional mature proteins. * **Option C:** This describes **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)** like Efavirenz or Nevirapine. They bind to a hydrophobic pocket on the enzyme (allosteric site) and do not require phosphorylation. * **Option D:** This is a broad description of protein synthesis inhibitors (like Macrolides or Aminoglycosides in bacteria), but it is not the primary mechanism of NRTIs. **High-Yield Clinical Pearls for NEET-PG:** * **Didanosine (ddI) Side Effects:** Most characteristic are **Pancreatitis** and **Peripheral Neuropathy**. * **Mitochondrial Toxicity:** NRTIs can inhibit mitochondrial DNA polymerase-gamma, leading to **Lactic Acidosis** and hepatic steatosis (Stavudine > Didanosine). * **Zidovudine (AZT):** Known for causing **Bone Marrow Suppression** (Anemia/Neutropenia). * **Abacavir:** Associated with a hypersensitivity reaction linked to the **HLA-B*5701** allele.

Question 795: Which drug is used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA)?

A. Teicoplanin
B. Vancomycin (Correct Answer)
C. Both
D. None

Explanation: **Explanation:** **1. Why Vancomycin is the Correct Answer:** Vancomycin is a glycopeptide antibiotic and has long been considered the **"Gold Standard"** for treating serious infections caused by Methicillin-Resistant *Staphylococcus aureus* (MRSA) [1]. It works by inhibiting bacterial cell wall synthesis by binding to the **D-Ala-D-Ala** terminus of the nascent peptidoglycan pentapeptide, preventing cross-linking [4]. Because MRSA carries the *mecA* gene (which alters Penicillin-Binding Protein 2a), it is resistant to almost all beta-lactams; however, it remains susceptible to the different mechanism of action provided by glycopeptides [3]. **2. Analysis of Other Options:** * **Teicoplanin (Option A):** Teicoplanin is also a glycopeptide antibiotic with a similar spectrum to Vancomycin and is highly effective against MRSA [2]. In clinical practice, it is often preferred due to its longer half-life (once-daily dosing) and lower nephrotoxicity [2]. * **Both (Option C):** While the provided key marks Vancomycin as the answer, in a standard clinical or pharmacological context, **"Both"** would technically be the most accurate choice as both drugs are frontline MRSA treatments. However, in many competitive exams, Vancomycin is prioritized as the "prototype" drug for MRSA. **3. NEET-PG High-Yield Clinical Pearls:** * **Red Man Syndrome:** A common adverse effect of Vancomycin caused by rapid IV infusion leading to direct histamine release (not a true IgE allergy). Prevented by slowing the infusion rate. * **Resistance Mechanism:** VRSA (Vancomycin-Resistant *S. aureus*) occurs due to the replacement of D-Ala-D-Ala with **D-Ala-D-Lac** [4]. * **Other MRSA Drugs:** Linezolid (oral/IV), Daptomycin (not for pneumonia), Ceftaroline (5th gen cephalosporin), and Tigecycline [1]. * **Drug of Choice for MRSA Colitis:** Oral Vancomycin (not absorbed systemically, acts locally in the gut) [3].

Question 796: According to WHO guidelines, which of the following drugs is NOT used in the treatment of leprosy?

A. Dapsone
B. Clofazimine
C. Ciprofloxacin (Correct Answer)
D. Rifampicin

Explanation: ### Explanation The treatment of leprosy (Hansen’s disease) is standardized by the **WHO Multi-Drug Therapy (MDT)** protocols. These protocols are designed to prevent the emergence of drug resistance and ensure the complete eradication of *Mycobacterium leprae*. **Why Ciprofloxacin is the correct answer:** While Ciprofloxacin (a fluoroquinolone) has some *in vitro* activity against *M. leprae*, it is **not** part of the standard WHO-recommended MDT regimens for either Paucibacillary (PB) or Multibacillary (MB) leprosy. In cases of drug resistance or intolerance to first-line agents, other fluoroquinolones like **Ofloxacin** or **Moxifloxacin** are preferred over Ciprofloxacin. **Analysis of Incorrect Options:** * **Rifampicin (Option D):** The most important bactericidal component of MDT. It inhibits bacterial DNA-dependent RNA polymerase. In WHO MDT, it is given as a once-monthly supervised dose (600 mg). * **Dapsone (Option A):** A bacteriostatic drug that inhibits dihydropteroate synthase (folate synthesis). It is a core component of both PB and MB regimens, administered as a daily self-administered dose (100 mg). * **Clofazimine (Option B):** A dye with weak bactericidal and anti-inflammatory properties. It is essential for the **Multibacillary (MB)** regimen and helps prevent/treat Type 2 Lepra reactions (ENL). **NEET-PG High-Yield Pearls:** * **Standard WHO MDT Duration:** PB Leprosy (6 months); MB Leprosy (12 months). * **ROM Regimen:** For single-lesion paucibacillary leprosy, a single dose of **R**ifampicin + **O**floxacin + **M**inocycline was previously used (though WHO now recommends the standard 6-month PB regimen for all PB cases). * **Clofazimine Side Effect:** Reddish-brown skin discoloration and ichthyosis are common "buzzwords" for exams. * **Dapsone Side Effect:** Hemolytic anemia (especially in G6PD deficiency) and "Dapsone Syndrome" (exfoliative dermatitis, hepatitis, and lymphadenopathy).

Question 797: Nevirapine belongs to which class of drugs?

A. Nucleoside Reverse Transcriptase Inhibitor
B. Protease inhibitor
C. Non Nucleoside Reverse Transcriptase Inhibitor (Correct Answer)
D. None of the above

Explanation: Explanation: **Nevirapine** is a potent and selective **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)** [1]. Unlike Nucleoside analogs, NNRTIs do not require intracellular phosphorylation to become active. They work by binding directly and non-competitively to a specific hydrophobic pocket on the HIV-1 Reverse Transcriptase enzyme (the NNRTI binding site), causing a conformational change that inhibits the conversion of viral RNA to DNA [3]. **Analysis of Options:** * **Option A (NRTI):** Drugs like Zidovudine, Abacavir, and Tenofovir are NRTIs [2]. They act as "false substrates" (analogs) and require phosphorylation to compete with natural nucleotides, causing DNA chain termination [2]. * **Option B (Protease Inhibitors):** Drugs ending in the suffix **"-navir"** (e.g., Ritonavir, Lopinavir) belong to this class. They inhibit the viral protease enzyme responsible for cleaving precursor polyproteins into functional mature proteins [4, 5]. * **Option D:** Incorrect, as Nevirapine is a well-established NNRTI. **High-Yield Clinical Pearls for NEET-PG:** * **HIV-2 Resistance:** NNRTIs (including Nevirapine and Efavirenz) are **ineffective against HIV-2**; they are only active against HIV-1. * **Prevention of Mother-to-Child Transmission (PMTCT):** A single dose of Nevirapine given to the mother at the onset of labor and to the neonate within 72 hours of birth significantly reduces vertical transmission [1, 3]. * **Adverse Effects:** The most significant side effects are **hepatotoxicity** (monitor LFTs) and **skin rashes**, which can rarely progress to life-threatening Stevens-Johnson Syndrome (SJS). * **Metabolism:** It is an inducer of CYP3A4 enzymes.

Question 798: Which of the following is a broad-spectrum systemic antifungal agent?

A. Econazole
B. Miconazole
C. Ketoconazole (Correct Answer)
D. Clotrimazole

Explanation: ### Explanation The correct answer is **Ketoconazole**. **1. Why Ketoconazole is correct:** Ketoconazole is a synthetic imidazole derivative that acts by inhibiting the enzyme **14-α-demethylase**, thereby blocking the synthesis of ergosterol (a vital component of the fungal cell membrane). While it was the first oral azole available for systemic use, it is a **broad-spectrum** agent effective against dermatophytes, *Candida*, and certain systemic mycoses (like Histoplasmosis and Blastomycosis). Although its systemic use has largely been replaced by more potent and less toxic triazoles (like Itraconazole), it remains the classic example of a systemic imidazole in pharmacological classifications. **2. Why the other options are incorrect:** * **Econazole, Miconazole, and Clotrimazole:** These are primarily **topical azoles**. While Miconazole has a parenteral formulation, it is rarely used systemically due to high toxicity. These agents are highly effective for superficial fungal infections (tinea, cutaneous candidiasis) but are not used as standard systemic treatments for deep-seated mycoses because they are either too toxic when given systemically or are rapidly metabolized. **3. High-Yield Clinical Pearls for NEET-PG:** * **Endocrine Side Effects:** Ketoconazole is unique because it inhibits human steroid synthesis (CYP450 enzymes). This leads to side effects like **gynecomastia**, loss of libido, and menstrual irregularities. * **Therapeutic Use:** Due to its ability to inhibit adrenal steroidogenesis, it is clinically used in the management of **Cushing’s Syndrome**. * **Absorption:** It requires an **acidic gastric pH** for absorption. Co-administration with H2 blockers or PPIs reduces its efficacy. * **Black Box Warning:** The FDA has issued warnings for Ketoconazole regarding **hepatotoxicity** and QTc prolongation.

Question 799: Which of the following is not a nucleoside reverse transcriptase inhibitor?

A. Zalcitabine
B. Lamivudine
C. Nevirapine (Correct Answer)
D. Didanosine

Explanation: **Explanation:** The question tests the classification of Antiretroviral Therapy (ART) drugs. Antiretrovirals are primarily divided into Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), and Integrase Inhibitors. **Why Nevirapine is the correct answer:** **Nevirapine** is a **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTIs)**. Unlike NRTIs, NNRTIs do not require phosphorylation to become active. They bind directly and non-competitively to a hydrophobic pocket on the HIV-1 Reverse Transcriptase enzyme (allosteric site), causing a conformational change that inhibits DNA polymerization. **Analysis of incorrect options (NRTIs):** NRTIs act as competitive inhibitors; they are analogs of native nucleosides that require intracellular phosphorylation to triphosphate forms. They get incorporated into the growing viral DNA chain, causing **chain termination**. * **Zalcitabine (ddC):** A cytosine analog NRTI (rarely used now due to toxicity). * **Lamivudine (3TC):** A potent cytosine analog NRTI, also used in Hepatitis B treatment. * **Didanosine (ddI):** An adenosine analog NRTI known for causing pancreatitis. **High-Yield Clinical Pearls for NEET-PG:** * **NNRTI Class Members:** Remember the "VIR" in the middle: Ne**vir**apine, Efa**vir**enz, Dela**vir**dine, Etra**vir**ine, Rilpi**vir**ine. * **Nevirapine Side Effects:** Most common are **skin rashes** (can progress to Stevens-Johnson Syndrome) and **hepatotoxicity**. * **Drug of Choice:** Nevirapine was historically used to prevent mother-to-child transmission (MTCT) of HIV, though it has largely been replaced by newer regimens. * **Mnemonic for NRTIs:** "ZAL (Zidovudine, Abacavir, Lamivudine) DID (Didanosine) STAV (Stavudine) TEN (Tenofovir - *Note: Tenofovir is a Nucleotide*)."

Question 800: Which antimicrobial agent is effective against ESBL-producing microorganisms?

A. Beta-lactam plus beta-lactamase inhibitor (Correct Answer)
B. Ampicillin
C. Ceftriaxone
D. Aztreonam

Explanation: Explanation: Extended-Spectrum Beta-Lactamases (ESBLs) are enzymes produced by certain bacteria (most commonly *E. coli* and *Klebsiella*) that mediate resistance by hydrolyzing the beta-lactam ring [2]. 1. Why Option A is Correct: ESBLs are typically inhibited by Beta-lactamase inhibitors (BLIs) such as Clavulanic acid, Sulbactam, and Tazobactam. Therefore, combinations like Piperacillin-Tazobactam or Cefoperazone-Sulbactam remain effective. However, note that Carbapenems (e.g., Meropenem) are clinically considered the "gold standard" treatment for serious ESBL infections [1]. 2. Why Options B, C, and D are Incorrect: * Ampicillin (B): ESBLs readily hydrolyze penicillins. * Ceftriaxone (C): By definition, ESBLs confer resistance to all 1st, 2nd, and 3rd generation cephalosporins (like Ceftriaxone and Ceftazidime) as well as 4th generation cephalosporins (Cefepime) [1][3]. * Aztreonam (D): ESBLs also hydrolyze Monobactams [1]. Aztreonam is only stable against Metallo-beta-lactamases (NDM-1), not ESBLs. High-Yield Clinical Pearls for NEET-PG: * The "Carbapenem Gap": While BLI combinations work *in vitro*, Carbapenems are the drugs of choice for ESBL-related urosepsis or bacteremia [1]. * Marker for ESBL: Resistance to Ceftazidime is often used as a laboratory screening marker for ESBL production. * Co-resistance: ESBL-producing organisms often carry genes for resistance to other classes, such as Fluoroquinolones and Aminoglycosides. * Exceptions: ESBLs do not hydrolyze Cephamycins (e.g., Cefoxitin, Cefotetan), though these are rarely used clinically for this purpose.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free